Regentis Biomaterials expanded the SAGE clinical trial of GelrinC to 11 U.S. sites. The investigational device is in evaluation to regrow knee cartilage.
SI-BONE closed its previously-announced initial public offering of 8,280,000 shares of common stock, priced at US $15 per share. The company is now trading on Nasdaq with the ticker symbol SIBN.
Merger and acquisition activity is shaping the broader orthopedic supply chain base, with contract manufacturers of all sizes transforming in the last decade to keep pace with their scaling device company customers. We've identified three M&A trends in this portion of the market.